Orelabrutinib for the treatment of relapsed or refractory MCL: a phase 1/2, open-label, multicenter, single-arm study

Relapsed or refractory (r/r) mantle cell lymphoma (MCL) is an aggressive B-cell malignancy with a poor prognosis. Bruton tyrosine kinase (BTK) is a mediator of B-cell receptor signaling and is associated with the development of B-cell lymphomas. Patients with r/r MCL were enrolled in this phase 1/2...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Li-Juan, Zhou, Ke-Shu, Liu, Li-Hong, Zhang, Ming-Zhi, Li, Zhi-Ming, Ji, Chun-Yan, Xu, Wei, Liu, Ting, Xu, Bing, Wang, Xin, Gao, Su-Jun, Zhang, Hui-Lai, Hu, Yu, Li, Yan, Cheng, Ying, Yang, Hai-Yan, Cao, Jun-Ning, Zhu, Zun-Min, Hu, Jian-Da, Zhang, Wei, Jing, Hong-Mei, Ding, Kai-Yang, Zhang, Xiang-Yang, Zhao, Ren-Bin, Zhang, Bin, Tian, Ya-Min, Song, Yong-Ping, Song, Yu-Qin, Zhu, Jun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Clinical Trials and Observations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432605/
https://www.ncbi.nlm.nih.gov/pubmed/37078706
http://dx.doi.org/10.1182/bloodadvances.2022009168

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10432605/
https://www.ncbi.nlm.nih.gov/pubmed/37078706
http://dx.doi.org/10.1182/bloodadvances.2022009168

Ejemplares similares